Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Arrevus logo — Conquering antibiotic resistance by targeting critical disea...

Arrevus

Conquering antibiotic resistance by targeting critical diseases with innovative DPCs.

Founded 2015 Grant Total: $2.05M Biotechnology, Pharmaceutical

General Information

Company Name Arrevus
Founded Year 2015
Industries Biotechnology, Pharmaceutical
Funding Stage Grant
Social

Get notified when Arrevus moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Arrevus

Arrevus is a biotechnology and pharmaceutical startup, founded in 2015, with a mission to address antibiotic resistance in critical diseases. The company's focus lies in developing Designer Proline-rich Antimicrobial Peptide Chaperone Protein Inhibitors (DPCs) for diseases where antibiotic resistance has significant clinical implications and limited treatment options. With their slogan "Conquering antibiotic resistance by targeting critical diseases with innovative DPCs," Arrevus aims to combat the impact of antibacterial resistance on patient health outcomes. Their last investment of $800.00K came in the form of a grant from the U.S. Department of Defense on 29 May 2020. Arrevus stands out for its dedication to addressing a pressing issue in the medical field and its strategic approach to drug development, positioning it as an impactful player in the fight against antibiotic resistance.

Taxonomy: antibiotic resistance, DPCs, drug development, clinical implications, bacterial resistance, MRSA, antimicrobial peptides, life-threatening diseases, patient outcomes, innovative therapies, pharmaceutical research, biomedical innovation

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Grant •••••• 1 •••• •••• 29 May 2020
Debt Financing •••••• 1 •••• •••• 16 Oct 2019
Venture Round •••••• - 26 May 2017

Arrevus Alternatives & Competitors

Arrevus vs
Shield Bio
Shield Bio

Combating antibiotic resistance through innovative genomic testing to ensure treatable infections re...

Pre Seed
Biotechnology, Health Care
Arrevus vs
Nuclease Probe Technologies, Inc.
Nuclease Probe Technologies, Inc. United States

Enabling early therapeutic intervention with low cost, rapid diagnostics

Seed
2 employees
Arrevus vs
Westway Health
Westway Health Ireland

Developing non-antibiotic antimicrobials

Series Unknown
1 employees
Biopharma, Biotechnology

FAQ About Arrevus

Conquering antibiotic resistance by targeting critical diseases with innovative DPCs.
Arrevus was founded in 2015.
Arrevus operates in the following industries: Biotechnology, Pharmaceutical.
Arrevus has completed 3 funding rounds, raising a total of $2.05M. The latest funding stage is Grant.
Top alternatives and competitors to Arrevus include Shield Bio, Nuclease Probe Technologies, Inc., Westway Health, AlgiPharma AS, phagos. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Arrevus and Shield Bio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Arrevus and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy